Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTPS1 | P17812 | 20/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30528738 | 0.95 | CTPS1 (0.64) | CTPS1 | |
| SCHEMBL22758482 | 0.93 | CTPS1 (0.65) | CTPS1 | |
| SCHEMBL22758489 | 0.90 | CTPS1 (0.66) | CTPS1 | |
| SCHEMBL29369501 | 0.90 | CTPS1 (0.66) | CTPS1 | |
| SCHEMBL22749225 | 0.90 | CTPS1 (0.66) | CTPS1 | |
| SCHEMBL29566153 | 0.90 | CTPS1 (0.66) | CTPS1 | |
| SCHEMBL22758533 | 0.89 | CTPS1 (0.78) | CTPS1 | |
| Hydrochloric Acid SCHEMBL28932323 | 0.88 | CTPS1 (0.77) | CTPS1 | |
| Hydrochloric Acid SCHEMBL29368809 | 0.88 | CTPS1 (0.77) | CTPS1 | |
| SCHEMBL22758469 | 0.88 | CTPS1 (0.80) | CTPS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4637770-A1 | CTPS1 INHIBITORS FOR USE IN THE TREATMENT OF CTPS2 DEFICIENT CANCER | Step Pharma S.A.S. (FR) | 2025-10-29 | — | — | EP | disclosed |
| EP-4486347-A1 | COMBINATIONS OF CTPS1 AND BCL2 INHIBITORS FOR CANCER | Step Pharma S.A.S. (FR) | 2025-01-08 | — | — | EP | disclosed |
| CN-118804752-A | Combination of CTPS1 and BCL2 inhibitors for the treatment of cancer | 斯泰普制药股份公司 | 2024-10-18 | — | — | CN | disclosed |
| WO-2024133721-A1 | COMBINATIONS OF CTPS1 INHIBITOR WITH IAP INHIBITOR FOR USE IN THE TREATMENT OF CANCER | STEP PHARMA S.A.S. (FR) | 2024-06-27 | — | — | WO | disclosed |
| WO-2023166076-A1 | COMBINATIONS OF CTPS1 AND BCL2 INHIBITORS FOR CANCER | STEP PHARMA S.A.S. (FR) | 2023-09-07 | — | — | WO | disclosed |
| WO-2023166080-A1 | COMBINATION TREATMENTS COMPRISING A CTPS1 INHIBITOR AND A WEE1 INHIBITOR | STEP PHARMA S.A.S. (FR) | 2023-09-07 | — | — | WO | disclosed |
| WO-2023166077-A1 | COMBINATION OF A CTPS1 INHIBITOR AND A ATR INHIBITOR IN CANCER THERAPY | STEP PHARMA S.A.S. (FR) | 2023-09-07 | — | — | WO | disclosed |
| WO-2023166078-A1 | COMBINATION TREATMENTS COMPRISING A CTPS1 INHIBITOR AND A CHEK1 INHIBITOR | STEP PHARMA S.A.S. (FR) | 2023-09-07 | — | — | WO | disclosed |
| WO-2020245665-A1 | N-(4-(5-CHLOROPYRIDIN-3-YL)PHENYL)-2-(2-(CYCLOPROPANESULFONAMIDO)PYRIMIDIN-4-YL) BUTANAMIDE DERIVATIVES AND RELATED COMPOUNDS AS HUMAN CTPS1 INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | STEP PHARMA S.A.S. (FR) | 2020-12-10 | — | — | WO | disclosed |